A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms
Recruiting
- Conditions
- IndigestionDyspepsiaBloatingLoss of AppetiteReflux AcidConstipationUpper Abdominal PainFunctional Dyspepsia
- Interventions
- Drug: Danning Tablet
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 4500
- Registration Number
- NCT06755671
- Locations
- 🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy
Phase 3
Recruiting
- Conditions
- Cervical Spondylotic Myelopathy
- Interventions
- Drug: Shenqi Sherong PillDrug: Placebo
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 428
- Registration Number
- NCT06377072
- Locations
- 🇨🇳
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China
Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
Phase 2
Active, not recruiting
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: 3 ampoules of SHPL-49 InjectionDrug: 0.9% Sodium Chloride InjectionDrug: 6 ampoules of SHPL-49 Injection
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 270
- Registration Number
- NCT06202378
- Locations
- 🇨🇳
Yuebei People's Hospital, Shaoguan, Guangdong, China
🇨🇳Hengshui People's Hospital, Hengshui, Hebei, China
🇨🇳Tangshan Workers' Hospital, Tangshan, Hebei, China
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
Phase 4
- Conditions
- Non Obstructive Coronary Artery DiseaseAngina PectorisX Syndrome, AnginaCoronary Heart Disease
- Interventions
- Drug: MUSK pill
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 264
- Registration Number
- NCT04984954
- Locations
- 🇨🇳
Huashan Hospital Fudan University, ShangHai, Shanghai, China
Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery
Phase 4
Completed
- Conditions
- Coronary Heart DiseaseAngina PectorisX Syndrome, AnginaIschemia With Non-Obstructive Coronary Artery
- Interventions
- Radiation: Shexiang Baoxin pill（MUSKARDIA）Radiation: Placebo
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 240
- Registration Number
- NCT04897126
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
A Trial to Evaluate Efficacy of Heart-protecting Musk Pill
Phase 4
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: PlaceboDrug: Heart-protecting Musk Pill
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 2700
- Registration Number
- NCT01897805
- Locations
- 🇨🇳
ShenZhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳The First People's Hospital of Liuzhou City, Liuzhou, Guangxi, China
🇨🇳The First Affiliated Hospital Of GuangXi University Of Chinese Medicine, Nanning, Guangxi, China
© Copyright 2025. All Rights Reserved by MedPath